荷兰全国范围内对既往开放或腔内腹主动脉瘤治疗行EVAS再衬的経験
该回顾性分析纳入2014至2019年荷兰7家高容量血管中心所有行EVAS再衬的患者,共33例(开放修复后10例、腔内修复后23例),技术成功率达97%,但中位随访20个月时临床成功率有限,开放修复后再衬的临床成功高于腔内修复后。
要点
- EVAS再衬的技术成功率为97%,住院死亡率为6%。
- 开放修复后再衬1年临床成功率为90%,腔内修复后为70%。
- 作者认为EVAS再衬仅应在既定技术(如开窗修复或开放转换)不可用或不适用时考虑。
核心结论
- EVAS再衬与高再通技术成功率相关,但在中位随访20个月时临床成功率有限。
- 开放修复后行EVAS再衬的患者临床成功率高于腔内修复后患者。
- 对于AAA修复失败的患者,仅当既定技术如开窗修复或开放转换不可用或不适用时,才应考虑EVAS再衬。
研究设计与样本
- 回顾性分析2014年至2019年荷兰7家高容量血管中心所有行EVAS再衬的患者,共33例。
- 其中开放修复后10例,腔内修复后23例;择期26例,急诊5例,急性(破裂)2例。
主要发现
- 初次治疗至EVAS再衬的平均时间为99±74个月。
- 开放修复后再衬指征为疾病近端进展(7例)和移植物缺陷(3例)。
- EVAR后再衬指征为IA型内漏(10例)、IB型(3例)、IIIA型(4例)、IIIB型(3例)及内张力(3例)。
- 18例接受常规EVAS,4例单侧EVAS,11例烟囱EVAS。
- 住院死亡率为6%(均为破裂性AAA患者),技术成功率为97%。
关键数值与推荐
- 再干预豁免率1年为83%,2年为61%;估计生存率1年为79%,2年为71%。
- 开放修复后再衬的临床成功率1年为90%,末次随访为70%;EVAR后再衬分别为70%和52%。
临床怎么用
- 作者认为,对于AAA修复失败的患者,EVAS再衬仅应在开窗修复或开放转换等既定技术不可用或不适用时考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Relining of a previously placed surgical graft or endograft for an abdominal aortic aneurysm (AAA) is a reintervention to treat progression of disease or failure of the primary (endo)graft. Endovascular Aneurysm Sealing (EVAS) relining is a technique with potential advantages due to the absence of a bifurcation, the possibility for a unilateral approach, and sealing concept of the endobags. The purpose of this study was to describe the nationwide experience with EVAS relining of previous AAA repair in the Netherlands. METHODS: A retrospective analysis of all patients who underwent EVAS relining in 7 high volume vascular centres in the Netherlands between 2014 and 2019 was performed. Primary outcomes were technical and clinical success. Secondary outcomes were perioperative outcomes, complications and survival. RESULTS: Thirty-three patients underwent EVAS relining of open (n = 10) or endovascular (n = 23) repair. 26 were elective cases, 5 were urgent and 2 were acute (ruptured). Mean time between primary treatment and EVAS relining was 99 ± 74 months. Indications after open repair were proximal progression of disease (n = 7) and graft defect (n = 3). Indications after EVAR were type IA (n = 10), type IB (n = 3), type IIIA (n = 4), type IIIB (n = 3) endoleak, and endotension (n = 3). 18 patients underwent regular EVAS, 4 unilateral EVAS and 11 chimney-EVAS. In-hospital mortality was 6% (both patients with rAAA). Technical success was achieved in 97%. Median follow-up after EVAS relining was 20 months (range 0-43). Freedom from reintervention at 1-year and 2-year were 83% and 61% and the estimated survival 79% and 71%, respectively. EVAS relining after open repair had a clinical success of 90% at 1-year and of 70% at latest follow-up, while after EVAR clinical success rates were 70% and 52%, respectively. CONCLUSION: EVAS relining of previous AAA repair is associated with high technical success, however with limited clinical success at median follow-up of 20 months. Clinical success was higher in patients with EVAS relining after open repair than after EVAR. In patients with failed AAA repair, EVAS relining should only be considered, when established techniques such as fenestrated repair or open conversion are not available or indicated.
引用
- Ketting S, Zoethout AC, Heyligers JMM, et al. Nationwide Experience with EVAS Relining of Previous Open or Endovascular AAA Treatment in The Netherlands. Ann Vasc Surg. 2022. PMID: 34998936. doi:10.1016/j.avsg.2021.12.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。